Evaluation of SPVN06 Gene Therapy Safety and Tolerability in Patients with Inherited Retinal Dystrophies, Specifically Rod Cone Dystrophy

The primary objective of this clinical study is to evaluate the **safety** and **tolerability** of SPVN06, a novel gene therapy, in patients with **rod cone dystrophy** (RCD), a subset of **inherited retinal dystrophies**. This evaluation is clinically relevant as it aims to determine the potential of SPVN06 to be a viable therapeutic option for managing RCD, a condition that currently lacks effective treatments. The study does not specify any secondary objectives.

The clinical trial involves a total of **16 participants** diagnosed with **inherited retinal dystrophies**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The selection process aimed to encompass a diverse group within the specified age range, ensuring a comprehensive understanding of the condition across different demographics.

The clinical trial is designed to evaluate the safety and tolerability of a novel gene therapy, SPVN06, in patients with **inherited retinal dystrophies**, specifically focusing on rod cone dystrophy. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is set to commence on April 1, 2023, with an estimated completion date of March 31, 2029, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and randomized to receive either the investigational product or a placebo. Throughout the trial, participants will attend regular follow-up visits to monitor safety, tolerability, and any adverse events. These visits are essential for collecting data on the primary and secondary endpoints of the study.

The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to evaluate the long-term effects of the treatment. The expected length of participant involvement is determined by the trial's duration, with each participant's involvement lasting until the end-of-study visit unless early termination is warranted. Conditions that may lead to early termination include significant adverse events, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial's design and procedures are meticulously planned to ensure the collection of robust and reliable data, contributing to the understanding of the investigational product's safety and efficacy in treating inherited retinal dystrophies.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is scheduled to commence recruitment on April 1, 2023, with an estimated completion date of March 31, 2029. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Efficacy assessments will be conducted throughout the trial period, although specific parameters or endpoints for evaluating efficacy, such as symptom improvement scores, biomarker levels, or disease remission rates, are not detailed in the available data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters, including any tools or instruments involved, are also not specified. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments.